JP2006514626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514626A5 JP2006514626A5 JP2004552854A JP2004552854A JP2006514626A5 JP 2006514626 A5 JP2006514626 A5 JP 2006514626A5 JP 2004552854 A JP2004552854 A JP 2004552854A JP 2004552854 A JP2004552854 A JP 2004552854A JP 2006514626 A5 JP2006514626 A5 JP 2006514626A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- substituted
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- -1 carbocyclyloxy Chemical group 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 2
- HDMMWSNTZNGSBX-UHFFFAOYSA-N 2-[(2-butan-2-yloxyquinoline-4-carbonyl)amino]-1,3-thiazole-5-carboxylic acid Chemical compound C=12C=CC=CC2=NC(OC(C)CC)=CC=1C(=O)NC1=NC=C(C(O)=O)S1 HDMMWSNTZNGSBX-UHFFFAOYSA-N 0.000 claims 1
- UFNAMURUPUJLQM-UHFFFAOYSA-N 2-[[2-[(2-chlorophenyl)methoxy]-6-methylquinoline-4-carbonyl]amino]-1,3-thiazole-5-carboxylic acid Chemical compound C1=C(C(=O)NC=2SC(=CN=2)C(O)=O)C2=CC(C)=CC=C2N=C1OCC1=CC=CC=C1Cl UFNAMURUPUJLQM-UHFFFAOYSA-N 0.000 claims 1
- XECBYHDEIIBBJP-UHFFFAOYSA-N 2-[[2-[(2-chlorophenyl)methoxy]quinoline-4-carbonyl]amino]-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(=O)O)=CN=C1NC(=O)C1=CC(OCC=2C(=CC=CC=2)Cl)=NC2=CC=CC=C12 XECBYHDEIIBBJP-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- PYMSEHFAUFQANC-UHFFFAOYSA-N 6-[[2-[(2-chlorophenyl)methoxy]-6-methylquinoline-4-carbonyl]amino]pyridine-3-carboxylic acid Chemical compound C1=C(C(=O)NC=2N=CC(=CC=2)C(O)=O)C2=CC(C)=CC=C2N=C1OCC1=CC=CC=C1Cl PYMSEHFAUFQANC-UHFFFAOYSA-N 0.000 claims 1
- QGYKSBSGPZJCPA-UHFFFAOYSA-N 6-[[2-[(2-chlorophenyl)methoxy]quinoline-4-carbonyl]amino]pyridine-3-carboxylic acid Chemical compound N1=CC(C(=O)O)=CC=C1NC(=O)C1=CC(OCC=2C(=CC=CC=2)Cl)=NC2=CC=CC=C12 QGYKSBSGPZJCPA-UHFFFAOYSA-N 0.000 claims 1
- IDWNZTWUCYIQKP-UHFFFAOYSA-N 6-[[4-[(2-methylphenyl)methoxy]quinoline-2-carbonyl]amino]pyridine-3-carboxylic acid Chemical compound CC1=CC=CC=C1COC1=CC(C(=O)NC=2N=CC(=CC=2)C(O)=O)=NC2=CC=CC=C12 IDWNZTWUCYIQKP-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 0 C*OC(C1=CC=CC=CCC(NC(c2c(cc(*)c(C)c3)c3nc(*)c2)=O)=C1)=O Chemical compound C*OC(C1=CC=CC=CCC(NC(c2c(cc(*)c(C)c3)c3nc(*)c2)=O)=C1)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0226931.4A GB0226931D0 (en) | 2002-11-19 | 2002-11-19 | Chemical compounds |
| PCT/GB2003/004915 WO2004045614A1 (en) | 2002-11-19 | 2003-11-13 | Quinoline derivatives as glucokinase ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514626A JP2006514626A (ja) | 2006-05-11 |
| JP2006514626A5 true JP2006514626A5 (enExample) | 2006-10-19 |
Family
ID=9948090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004552854A Withdrawn JP2006514626A (ja) | 2002-11-19 | 2003-11-13 | グルコキナーゼリガンドとしてのキノリン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7230108B2 (enExample) |
| EP (1) | EP1583532B1 (enExample) |
| JP (1) | JP2006514626A (enExample) |
| AT (1) | ATE401076T1 (enExample) |
| AU (1) | AU2003282233A1 (enExample) |
| DE (1) | DE60322267D1 (enExample) |
| ES (1) | ES2307992T3 (enExample) |
| GB (1) | GB0226931D0 (enExample) |
| WO (1) | WO2004045614A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| FR2864535B1 (fr) | 2003-12-24 | 2006-12-22 | Merck Sante Sas | Derives acides de quinoline et leurs applications en therapeutique |
| EP2048137A1 (en) * | 2004-02-18 | 2009-04-15 | AstraZeneca AB | Benzamide derivatives and their use as glucokinase activating agents. |
| JP2007523905A (ja) * | 2004-02-18 | 2007-08-23 | アストラゼネカ アクチボラグ | 化合物 |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| BRPI0516595A (pt) * | 2004-10-16 | 2008-09-23 | Astrazeneca Ab | processo para fabricar um composto, e, composto |
| GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| EP1891069A1 (en) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| KR20110084339A (ko) * | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| US20110053910A1 (en) * | 2005-07-09 | 2011-03-03 | Mckerrecher Darren | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
| WO2007017649A1 (en) * | 2005-08-09 | 2007-02-15 | Astrazeneca Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
| US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| EP1948652B1 (en) * | 2005-11-01 | 2011-08-24 | Array Biopharma, Inc. | Glucokinase activators |
| TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| EP2001875A2 (en) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| EP2010520B1 (en) * | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| TW200825060A (en) * | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| MX2009006729A (es) | 2006-12-21 | 2009-08-07 | Astrazeneca Ab | Nuevo compuesto cristalino util como activador de glk. |
| WO2008116107A2 (en) | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| MX2011001333A (es) | 2008-08-04 | 2011-03-15 | Astrazeneca Ab | Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad. |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
| PL2424529T3 (pl) | 2009-04-30 | 2017-06-30 | Midwestern University | Nowe postępowania terapeutyczne z zastosowaniem centakwiny |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012158474A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| PE20191616A1 (es) | 2017-04-10 | 2019-11-05 | Bayer Ag | N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso |
| CN112469474A (zh) | 2018-05-03 | 2021-03-09 | 美国中西部大学 | 出血和centhaquin引起的复苏后内皮素受体的变化 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1561350A (en) * | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
| US5792109A (en) | 1994-09-01 | 1998-08-11 | Leland L. Ladd | Irrigation pump and system |
| JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
| JP3168915B2 (ja) | 1995-05-25 | 2001-05-21 | 田辺製薬株式会社 | 医薬組成物 |
| US6613942B1 (en) * | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | ５−アミノイソキサゾール誘導体 |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| HK1046139B (zh) * | 1999-03-29 | 2004-12-10 | 霍夫曼-拉罗奇有限公司 | 葡糖激酶活化剂 |
| GB9921684D0 (en) | 1999-09-15 | 1999-11-17 | Zeneca Ltd | Assays |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| EP1282612B1 (en) | 2000-05-03 | 2004-12-29 | F. Hoffmann-La Roche Ag | Alkynyl phenyl heteroaromatic glucokinase activators |
| ATE304011T1 (de) | 2000-05-03 | 2005-09-15 | Hoffmann La Roche | Hydantoin-enthaltende glucokinase aktivatoren |
| BR0110704A (pt) | 2000-05-08 | 2003-01-28 | Hoffmann La Roche | Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase |
| MXPA02010795A (es) | 2000-05-08 | 2003-03-27 | Hoffmann La Roche | Activadores de glucocinasa de fenilamida sustituida por para-amino. |
| HK1052351B (en) | 2000-06-28 | 2006-11-03 | Japan Tobacco Inc. | Benzothiazolyl ppar-gamma modulators |
| CA2416229C (en) | 2000-07-20 | 2007-09-18 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| US7053105B2 (en) | 2000-09-25 | 2006-05-30 | Janssen Pharmaceutica, N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| EP1341774B1 (en) * | 2000-12-06 | 2006-02-01 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| CA2460075A1 (en) | 2001-09-12 | 2003-03-20 | Donn Gregory Wishka | Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases |
| US7544690B2 (en) | 2001-10-01 | 2009-06-09 | Taisho Pharmaceutical Co., Ltd. | MCH receptor antagonists |
| EP1453541A1 (en) | 2001-12-03 | 2004-09-08 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
| AR037641A1 (es) | 2001-12-05 | 2004-11-17 | Tularik Inc | Moduladores de inflamacion |
| US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
| KR101018318B1 (ko) | 2001-12-21 | 2011-03-04 | 노보 노르디스크 에이/에스 | Ｇｋ 활성제로서의 아미드 유도체 |
| WO2003080585A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| CN100357283C (zh) | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
| BR0309546A (pt) | 2002-04-26 | 2005-02-15 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii |
| AU2003235307A1 (en) | 2002-05-16 | 2003-12-02 | Banyu Pharmaceutical Co., Ltd. | Crystal of glucokinase protein, and method for drug design using the crystal |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| PL375021A1 (en) | 2002-10-03 | 2005-11-14 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| ES2293005T3 (es) | 2002-10-03 | 2008-03-16 | F. Hoffmann-La Roche Ag | Indol-3-carboxamidas como activadores de la glucocinasa. |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004063179A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
| WO2004063194A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| JP4621198B2 (ja) | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ（シクロ）置換アミドグルコキナーゼ活性化化合物 |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| BRPI0407283A (pt) | 2003-02-13 | 2006-01-31 | Banyu Pharma Co Ltd | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| US7728025B2 (en) | 2003-12-29 | 2010-06-01 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted benzimidazole derivative |
| BRPI0506662B8 (pt) | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| JP2007523905A (ja) | 2004-02-18 | 2007-08-23 | アストラゼネカ アクチボラグ | 化合物 |
| EP2048137A1 (en) | 2004-02-18 | 2009-04-15 | AstraZeneca AB | Benzamide derivatives and their use as glucokinase activating agents. |
| AU2005223610B2 (en) | 2004-03-23 | 2008-05-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| PT1735322E (pt) | 2004-04-02 | 2012-01-12 | Novartis Ag | Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2 |
| US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| EA012204B1 (ru) | 2004-04-21 | 2009-08-28 | Прозидион Лимитед | Три(цикло)замещённые амидные соединения |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| EP1758611A2 (en) | 2004-06-17 | 2007-03-07 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
| MX2007001650A (es) | 2004-08-12 | 2007-07-13 | Prosidion Ltd | Fenilacetamidas substituidas y su uso como activadores de glucocinasa. |
| GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| BRPI0516595A (pt) | 2004-10-16 | 2008-09-23 | Astrazeneca Ab | processo para fabricar um composto, e, composto |
| GB0423043D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
-
2002
- 2002-11-19 GB GBGB0226931.4A patent/GB0226931D0/en not_active Ceased
-
2003
- 2003-11-13 WO PCT/GB2003/004915 patent/WO2004045614A1/en not_active Ceased
- 2003-11-13 JP JP2004552854A patent/JP2006514626A/ja not_active Withdrawn
- 2003-11-13 ES ES03773851T patent/ES2307992T3/es not_active Expired - Lifetime
- 2003-11-13 EP EP03773851A patent/EP1583532B1/en not_active Expired - Lifetime
- 2003-11-13 AT AT03773851T patent/ATE401076T1/de not_active IP Right Cessation
- 2003-11-13 US US10/534,651 patent/US7230108B2/en not_active Expired - Fee Related
- 2003-11-13 DE DE60322267T patent/DE60322267D1/de not_active Expired - Fee Related
- 2003-11-13 AU AU2003282233A patent/AU2003282233A1/en not_active Abandoned